FORMULATION AND QBD BASED OPTIMIZATION OF METHOTREXATE-LOADED SOLID LIPID NANOPARTICLES FOR AN EFFECTIVE ANTI-CANCER TREATMENT

CHAITALI SURVE; RUCHI SINGH; ANANYA BANERJEE; SRINIVAS PATNAIK; SUPRIYA SHIDHAYE

doi:10.22159/ijap.2021v13i5.42373

Authors

CHAITALI SURVE Department of Pharmaceutics, Vivekanand Education Society’s College of Pharmacy, Mumbai 400074, India
RUCHI SINGH Department of Quality Assurance, Vivekanand Education Society’s College of Pharmacy, Mumbai, India
ANANYA BANERJEE School of Biotechnology, KIIT University, Bhubaneswar, India
SRINIVAS PATNAIK School of Biotechnology, KIIT University, Bhubaneswar, India
SUPRIYA SHIDHAYE Department of Pharmaceutics, Vivekanand Education Society’s College of Pharmacy, Mumbai 400074, India

DOI:

https://doi.org/10.22159/ijap.2021v13i5.42373

Keywords:

Oral route, Methotrexate, Solid lipid nanoparticles, Glycerol monostearate, Factorial design

Abstract

Objective: In the current study, the Quality by Design method was utilized for the formulation of solid lipid nanoparticles of Methotrexate (MTX SLNs).

Methods: MTX SLNs formulated by melt emulsification method were studied for the effect of independent variables viz. concentration of lipid and surfactants on quality attributes viz. particle size, polydispersity index, and entrapment efficiency of SLNs using 3² factorial design.

Results: The optimal formulation was spherical, had a particle size of 147.6±4.1 nm (z-average), a polydispersity index of 0.296±0.058, a zeta potential of −19±0.98 mV, encapsulation efficiency of 98.7±1.55%, and a cumulative drug release of 95.59±0.918% in 5 h.

Conclusion: The in vitro and in vivo studies revealed that SLNs provide a promising oral delivery system to improve the bioavailability of MTX.

Downloads

Download data is not yet available.

References

Yoon SA, Choi JR, Kim JO, Shin JY, Zhang X, Kang JH. Influence of reduced folate carrier and dihydrofolate reductase genes on methotrexate-induced cytotoxicity. Cancer Res Treat 2010;42:163.

Khan ZA, Tripathi R, Mishra B. Methotrexate: a detailed review on drug delivery and clinical aspects. Expert Opin Drug Delivery 2012;9:151–69.

Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004;1:85–96.

Chen YH, Tsai CY, Huang PY, Chang MY, Cheng PC, Chou CH, et al. Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. Mol Pharm 2007;4:713–22.

Nogueira DR, Tavano L, Mitjans M, Perez L, Infante MR, Vinardell MP. In vitro antitumor activity of methotrexate via pH-sensitive chitosan nanoparticles. Biomaterials 2013;34:2758–72.

Thomas TP, Huang B, Choi SK, Silpe JE, Kotlyar A, Desai AM, et al. Polyvalent dendrimer-methotrexate as a folate receptor-targeted cancer therapeutic. Mol Pharm 2012;9:2669–76.

Liang LS, Jackson J, Min W, Risovic V, Wasan KM, Burt HM. Methotrexate loaded poly(L-Lactic Acid) microspheres for intra-articular delivery of methotrexate to the joint. J Pharm Sci 2004;93:943–56.

Smal MA, Dong Z, Cheung HTA, Asano Y, Escoffier L, Costello M, et al. Activation and cytotoxicity of 2-α-aminoacyl prodrugs of methotrexate. Biochem Pharmacol 1995;49:567–74.

Kang H, Kim JD, Han SH, Chang IS. Self-aggregates of poly(2-hydroxyethyl aspartamide) copolymers loaded with methotrexate by physical and chemical entrapments. J Controlled Release 2002;81:135–44.

Baek JS, Cho CW. Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles. Int J Pharm 2015;478:617–24.

Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Reports 2012;64:1020–37.

Mader K, Mehnert W. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Delivery Rev 2001;47:165–96.

No Title, ICH Q9, June 2006 US food drug adm guid ind q9 qual risk manag. Available from: http//www.ich.org/ fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R 1/Step4/Q8_R2_Guideline.pdf. [Last accessed on 05 May 2021]

No Title, ICH Q8 (R2), August 2009 Pharm Dev. Available from: http//www.fda.gov/downloads/Drugs/./Guidances/ucm073511.pdf. [Last accessed on 05 May 2021]

No Title, Wechsler J, 2008 FDA Propos Flex Overs Qual Syst Pharm Technol. Available from: http//www.pharmtech.com/ node/227632?rel=canonical. [Last accessed on 05 May 2021]

Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Controlled Release 2009;133:238–44.

Wang J, Zhu R, Sun X, Zhu Y, Liu H, Wang SL. Intracellular uptake of etoposide-loaded solid lipid nanoparticles induces an enhancing inhibitory effect on gastric cancer through the mitochondria-mediated apoptosis pathway. Int J Nanomed 2014;9:3987–98.

Shah B, Khunt D, Bhatt H, Misra M, Padh H. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur J Pharm Sci 2015;78:54–66.

Tuanwei L, Xiao L, Jilan W, Ping Z, Xiaoying H, Zhide Z, et al. Ag@ S-nitrosothiol core-shell nanoparticles for chemo and synergistic photothermal tumor-targeted therapy. J Materials Chem B 2020;8:5483-90.

Chen J, Huang L, Lai H, Lu C, Fang M, Zhang Q, et al. Methotrexate-loaded PEGylated chitosan nanoparticles: synthesis, characterization, and in vitro and in vivo antitumoral activity. Mol Pharm 2014;11:2213-23.

Ji P, Yu T, Liu Y, Jiang J, Xu J, Zhao Y, et al. Naringenin-loaded solid lipid nanoparticles: Preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics. Drug Des Dev Ther 2016;10:911–25.

Kumar A, Pandit V, Nagaich U. Therapeutic evaluation of chemically synthesized copper nanoparticles to promote full-thickness excisional wound healing. Int J Appl Pharm 2020;12:136-42.

Patel M, Patel NV, Patel TB. Design and development of rilpivirine nanoparticle-containing chitosan using ionic gelation method for HIV infections. Int J Pharm Pharm Sci 2020;12:113-8.

Gandamalla D, Iingabathula H, Yellu NR. Cytotoxicity evaluation of titanium and zinc oxide nanoparticles on human cell lines. Int J Pharm Pharm Sci 2017;9:240-6.

Abdelmonem R, El-nabarawi MA, Attia AM, Teaimaa M. Ocular delivery of natamycin solid lipid nanoparticle loaded mucoadhesive gel: formulation, characterization and in vivo study. Int J Appl Pharm 2020;12:173-80.

Gardouh AR, Gad S, Ghonaim HM, Ghorab MM. Design and characterization of glyceryl monostearate solid lipid nanoparticles prepared by high shear homogenization. J Pharm Res Int 2013;3:326-46.

Jamil l, Jan SU, Gul R. Formulation of microemulsion based gel of salbutamol sulphate and it’s in vitro studies. Int J Curr Pharm Sci 2020;12:102-7.

Liu J, Gong T, Wang C, Zhong Z, Zhang Z. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm 2007;340:153-62.

Zhang Y, Zhuo R. Synthesis and drug release behavior of poly (trimethylene carbonate)–poly (ethylene glycol)–poly (trimethylene carbonate) nanoparticles. Biomaterials 2005;26:2089-94.

Jingou J, Shilei H, Weiqi L, Danjun W, Tengfei W, Yi X. Preparation, characterization of hydrophilic and hydrophobic drug in combine loaded chitosan/cyclodextrin nanoparticles and in vitro release study. Colloids Surf B 2010;83:103-7.

Lou H, Gao L, Wei X, Zhang Z, Zheng D, Zhang D, et al. Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor-bearing mice. Colloids Surf B 2011;87:319–25.

Ghosh S, More P, Derle A, Kitture R, Kale T, Gorain M, et al. Diosgenin functionalized iron oxide nanoparticles as novel nanomaterial against breast cancer. J Nanosci Nanotechnol 2015;15:9464–72.

Zhao Y, Guo Y, Li R, Wang T, Han M, Zhu C, et al. Methotrexate nanoparticles prepared with codendrimer from polyamidoamine (PAMAM) and oligoethylene glycols (OEG) dendrons: antitumor efficacy in vitro and in vivo. Sci Rep 2016;6:28983.